IFNα Kinoid (IFN-K)
Systemic Lupus Erythematosus (SLE)
Key Facts
About Neovacs
Founded in 1993, Neovacs is a Paris-based biotech that historically focused on its innovative Kinoid® active immunotherapy platform, designed to induce a patient's own immune system to regulate harmful cytokines. Following a judicial reorganization in 2020, the company pivoted to a hybrid model, pairing the management of its legacy pipeline with strategic investments in external biotech and medtech companies. This strategy aims to leverage internal expertise for portfolio growth while seeking to revive its core R&D programs under improved financial conditions.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| hCDR1 (Edratide) | XTL Biopharmaceuticals | Phase 2 |
| Nipocalimab | Johnson and Johnson Innovative Medicine | Phase 3 |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| Brepocitinib (PF-06700841) | Priovant Therapeutics | Phase 3 |
| aiSLE® DX Flare Risk Index | Progentec Diagnostics | Commercial |
| aiSLE® DX Disease Activity Index | Progentec Diagnostics | Commercial |
| OASIS Study (Digital Biomarkers) | Progentec Diagnostics | Clinical Study |
| RSLV-132 | Resolve Therapeutics | Phase 2 |
| Mini-CAR for SLE | Caravan Biologix | Pre-clinical |
| Internal Program | BenevolentAI | Preclinical |
| Cenerimod | Ono Pharmaceutical | Phase 3 |
| HDM3001 (PRV-3279) | Huadong Medicine (HD Medicine) | Phase II |